Viridian Therapeutics, Inc.\DE (VRDN) Asset Utilization Ratio (2014 - 2026)
Viridian Therapeutics, Inc.\DE (VRDN) posted quarterly Asset Utilization Ratio of 0.08 for Q1 2026, up 19418.29% year-over-year from N/an in Q1 2025, and down 12.46% quarter-over-quarter from 0.1 in Q4 2025.
Powered by 
Analysis
Viridian Therapeutics, Inc.\DE (VRDN) Asset Utilization Ratio (2014 - 2026) Analysis & Trends
Viridian Therapeutics, Inc.\DE's Asset Utilization Ratio history runs 13 years deep, the most recent figure standing at 0.08 for Q1 2026.
- In Q1 2026, Asset Utilization Ratio rose 19418.29% year-over-year to 0.08; the TTM figure through Mar 2026 stood at 0.08 (up 19418.29% YoY), while the FY2025 annual figure was 0.09, up 17515.83% from the prior year.
- Asset Utilization Ratio for Q1 2026 stood at 0.08, down from 0.1 in the prior quarter.
- The five-year high for Asset Utilization Ratio was 0.12 in Q3 2025, with the low at 0.0 in Q4 2024.
- The 5-year median for Asset Utilization Ratio is 0.0 (2023), against an average of 0.02.
- The sharpest annual moves came in 2024 and 2025: Asset Utilization Ratio slumped 88.11% in 2024, then surged 27344.94% in 2025.
- Viridian Therapeutics, Inc.\DE's Asset Utilization Ratio stood at 0.0 in 2022, then tumbled by 81.06% to 0.0 in 2023, then slumped by 47.97% to 0.0 in 2024, then jumped by 23959.67% to 0.1 in 2025, then decreased by 12.46% to 0.08 in 2026.
- Business Quant data shows VRDN's Asset Utilization Ratio at 0.08 in Q1 2026, 0.1 in Q4 2025, and 0.12 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 0.47 |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 0.38 |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 0.20 |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 0.69 |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 0.90 |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 0.13 |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 0.54 |
| 10 | Viridian Therapeutics, Inc.\DE | 2.42 Bn | 2.42 Bn | - | 0.08 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 0.08 |
| Mar 31, 2026 | 0.08 |
| Dec 31, 2025 | 0.10 |
| Sep 30, 2025 | 0.12 |
| Jun 30, 2025 | 0.00 |
| Mar 31, 2025 | 0.00 |
| Dec 31, 2024 | 0.00 |
| Sep 30, 2024 | 0.00 |
| Jun 30, 2024 | 0.00 |
| Mar 31, 2024 | 0.00 |
| Dec 31, 2023 | 0.00 |
| Sep 30, 2023 | 0.00 |
| Jun 30, 2023 | 0.00 |
| Mar 31, 2023 | 0.00 |
| Dec 31, 2022 | 0.00 |
| Sep 30, 2022 | 0.01 |
| Jun 30, 2022 | 0.01 |
| Mar 31, 2022 | 0.01 |
| Dec 31, 2021 | 0.01 |
| Sep 30, 2021 | 0.02 |